PhI­II win for smok­ing ces­sa­tion treat­ment puts Achieve Life Sci­ences on path to FDA, jazzes up deal talks

A spe­cial­ty phar­ma out to bring a smok­ing ces­sa­tion treat­ment long used in Cen­tral and East­ern Eu­rope to the US says it’s cleared the fi­nal hur­dle be­fore fil­ing with the FDA.

Achieve Life Sci­ences, which is based in Seat­tle and Van­cou­ver, said its can­di­date, cytisini­cline, met the pri­ma­ry and sec­ondary end­points in a con­fir­ma­to­ry Phase III tri­al, more than a year af­ter it an­nounced a win for its first Phase III tri­al. With both six- and 12-week treat­ment cy­cles, the drug im­proved the odds that study par­tic­i­pants could quit smok­ing — and stay ab­sti­nent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER